Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.
about
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyTailoring the Treatment of Melanoma: Implications for Personalized MedicineTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondCrystal structure of a BRAF kinase domain monomer explains basis for allosteric regulationRAF inhibitors that evade paradoxical MAPK pathway activationChemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E ConformationMitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant TransformationHierarchical scaffolding of an ERK1/2 activation pathwayThe epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic fluxC-Raf deficiency leads to hearing loss and increased noise susceptibility.Development of siRNA payloads to target KRAS-mutant cancer.Drugging the undruggable RAS: Mission possible?Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation.SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants.BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.CRAF R391W is a melanoma driver oncogenePhospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.Inhibition of RAS function through targeting an allosteric regulatory site.Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.The importance of Raf dimerization in cell signalingBioportides: bioactive cell-penetrating peptides that modulate cellular dynamics.Tumor adaptation and resistance to RAF inhibitors."RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway.No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.Targeting RAS-mutant cancers: is ERK the key?Catalytic mechanisms and regulation of protein kinases.BRAF inhibitors: experience in thyroid cancer and general review of toxicity.The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1.A-Raf: A new star of the family of raf kinases.CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.The renewed battle against RAS-mutant cancers.An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity.Allosteric activation of functionally asymmetric RAF kinase dimers.KSR as a therapeutic target for Ras-dependent cancers.Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
P2860
Q26771192-351F5B3B-8DA7-4C30-94CD-A21D44FD3535Q26775806-D8D577FE-BD3E-453D-A7A1-D734967144E0Q27026323-CD9D9AB0-7A9B-469C-B09F-A9F65AA6F286Q27696239-E5A76DB2-9FFA-4E86-8A5D-C88B69238D6DQ27702299-6E93863F-AC86-4A88-9588-EF31B6872CA2Q27727954-13BDD885-F9EA-40F4-A168-B5A98C6323F9Q28548302-07E2EA5C-A89A-454A-9227-9A23EDE20B35Q28578122-57560253-5DB5-4A01-A5B1-0D25E14833A2Q28607006-96BF07B6-DF57-48B2-AD00-1C632D2E0A98Q30664961-A182CC57-8AE1-4ECB-82CE-5C21AE5ADECDQ34287993-7419E5F1-731C-4A5F-B581-B6E5AA5E555BQ35163434-22655475-11FB-4603-B012-35877DEDA7F1Q35790764-A052237E-A4EE-4DBA-8B4D-9A41E2D738F4Q36098356-AA2CF4C8-2DC6-4C0B-930C-522D38448620Q36478826-9CBB02DB-B926-4F74-814A-0F020297EDB9Q36973111-34FD0A0E-4ABD-467C-BC43-EDDAE076B907Q36980239-41D63B41-5C25-44CB-8354-A86F4B70DAFCQ37295744-24E9CA5F-28C8-4B7B-A7CA-F6512DFD97A5Q37540897-2695554F-2AC2-4B35-9C40-0323B9B8DE54Q37632230-915F76D9-AEA6-45CA-8028-D7F0F707BC60Q37686994-5CCF36CC-B8D9-4FC7-8775-57C494EB291AQ38120721-47CAF862-EF85-41D8-B6EE-EFA492DEBF1EQ38160738-FE321C43-50F8-4932-9315-CFDEEE188C05Q38220879-FB273DCF-3DC5-4540-8D0C-77553E2ADEFFQ38245356-B4AAFB43-2D61-41CD-B5AF-229CD823588DQ38259819-3017C0B3-45A7-43FB-A3D7-8A377C59FB58Q38267209-E78C0599-C54A-40AD-8804-31F6D465A277Q38268502-3E3B53BB-4106-452B-A9EE-9EE3EE15913BQ38281838-148C031A-A0D5-43D8-ADFD-111D287FDA90Q38358817-842F8013-5556-42EA-A60D-E1C4E356798BQ38615220-EA81799D-004D-4F44-8A70-D7118F26048AQ38618036-76FF1C19-F21A-49FA-A71A-DFFC7FAA5AA1Q38625816-9496306D-3AD4-430B-AB91-7643896DB6C2Q38740000-71B31B47-5874-429E-8E07-2431C91FBB9DQ38752000-3215D80C-56B1-41FA-AD1B-055D7F4F36BBQ38981868-CB5F5FAD-AF0D-4A3C-97A1-A59F0E97B88DQ39102460-08388411-0E9F-4A45-A002-BDFD4865BBACQ39195762-CDC6D653-DE53-47BF-A4F6-4870E59C09E7Q40209192-05F399D7-88B8-40C3-8B6F-5A7626BF592FQ40240418-D58D1819-DAC6-4BCC-9824-F9713A4E5B61
P2860
Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Effects of Raf dimerization an ...... ease-associated Raf signaling.
@ast
Effects of Raf dimerization an ...... ease-associated Raf signaling.
@en
type
label
Effects of Raf dimerization an ...... ease-associated Raf signaling.
@ast
Effects of Raf dimerization an ...... ease-associated Raf signaling.
@en
prefLabel
Effects of Raf dimerization an ...... ease-associated Raf signaling.
@ast
Effects of Raf dimerization an ...... ease-associated Raf signaling.
@en
P2093
P2860
P1433
P1476
Effects of Raf dimerization an ...... ease-associated Raf signaling.
@en
P2093
Alyson K Freeman
Daniel A Ritt
Deborah K Morrison
P2860
P304
P356
10.1016/J.MOLCEL.2012.12.018
P577
2013-01-24T00:00:00Z